{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:43:28Z","timestamp":1771332208778,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.iac.2023.05.001","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T15:53:43Z","timestamp":1687276423000},"page":"743-750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis"],"prefix":"10.1016","volume":"43","author":[{"given":"Cem","family":"Akin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.iac.2023.05.001_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaip.2018.09.024","article-title":"Study Group of the European Competence Network on Mastocytosis (ECNM). The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives","volume":"7","author":"Valent","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.iac.2023.05.001_bib2","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"issue":"8","key":"10.1016\/j.iac.2023.05.001_bib3","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/all.14248","article-title":"Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification","volume":"75","author":"Trizuljak","year":"2020","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.iac.2023.05.001_bib4","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.jaip.2022.03.007","article-title":"Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice","volume":"10","author":"Valent","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"20","key":"10.1016\/j.iac.2023.05.001_bib5","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cncr.34420","article-title":"Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey","volume":"128","author":"Mesa","year":"2022","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.iac.2023.05.001_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaci.2004.04.046","article-title":"The biology of Kit in disease and the application of pharmacogenetics","volume":"114","author":"Akin","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2023.05.001_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"7","key":"10.1016\/j.iac.2023.05.001_bib8","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.iac.2023.05.001_bib9","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iac.2023.05.001_bib10","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jaci.2022.04.020","article-title":"Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?","volume":"149","author":"Akin","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2023.05.001_bib11","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.iac.2023.05.001_bib12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","article-title":"KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities","volume":"120","author":"Maric","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"40","key":"10.1016\/j.iac.2023.05.001_bib13","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KITmutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.iac.2023.05.001_bib14","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A\u00a0novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.iac.2023.05.001_bib15","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jaip.2022.03.001","article-title":"Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group","volume":"10","author":"Hoermann","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2023.05.001_bib16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.iac.2023.05.001_bib17","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"issue":"26","key":"10.1016\/j.iac.2023.05.001_bib18","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iac.2023.05.001_bib19","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2023.05.001_bib20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2023.05.001_bib21","doi-asserted-by":"crossref","first-page":"E138","DOI":"10.1002\/ajh.26464","article-title":"Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience","volume":"97","author":"Farrukh","year":"2022","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.iac.2023.05.001_bib22","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.iac.2023.05.001_bib23","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.iac.2023.05.001_bib24","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/s41591-021-01588-z","article-title":"Finding the right KIT inhibitor for advanced systemic mastocytosis","volume":"27","author":"Castells","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.iac.2023.05.001_bib25","doi-asserted-by":"crossref","unstructured":"Akin, Cem et\u00a0al. PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy. Journal of Allergy and Clinical Immunology, Volume 145, Issue 2, AB336.","DOI":"10.1016\/j.jaci.2019.12.062"},{"key":"10.1016\/j.iac.2023.05.001_bib26","doi-asserted-by":"crossref","unstructured":"Castells, Mariana et\u00a0al., Efficacy and Safety of Avapritinib in Indolent Systemic Mastocytosis (ISM): Results from the Double Blinded Placebo-Controlled PIONEER Study Journal of Allergy and Clinical Immunology, Volume 151, Issue 2, AB204.","DOI":"10.1016\/j.jaci.2022.12.635"},{"key":"10.1016\/j.iac.2023.05.001_bib27","unstructured":"www.blueprintmedicines.com\/wp-content\/uploads\/2023\/02\/Blueprint-Medicines-AAAAI-2023-Avapritinib-Indolent-SM-PIONEER-Efficacy-Safety-Oral-Presentation.pdf. Accessed May 15, 2023."},{"issue":"6","key":"10.1016\/j.iac.2023.05.001_bib28","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"New Engl J Med Evid"},{"issue":"1","key":"10.1016\/j.iac.2023.05.001_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/hematology.2022000368","article-title":"Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms","volume":"2022","author":"Gotlib","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.iac.2023.05.001_bib30","doi-asserted-by":"crossref","unstructured":"Castells M, Bhavsar V, He K, Scherber R, Akin C. HARBOR, a phase 2\/3 study of BLU-263 in patients with indolent systemic mastocytosis and monoclonal mast cell activation syndrome abstract. Paper presented at: European Hematology Association Congress; 10 June 2022; Vienna, Austria.","DOI":"10.1097\/01.HS9.0000846936.51452.f2"},{"key":"10.1016\/j.iac.2023.05.001_bib31","unstructured":"www.blueprintmedicines.com\/wp-content\/uploads\/2022\/02\/Blueprint-Medicines-AAAAI-2022-HARBOR-BLU-263-Indolent-Systemic-Mastocytosis.pdf Accessed May 15, 2023."},{"key":"10.1016\/j.iac.2023.05.001_bib32","doi-asserted-by":"crossref","unstructured":"Akin C. Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). ASH; 2022 cited 2023 Mar 14. Available from: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper156326.html.","DOI":"10.1182\/blood-2022-156326"},{"key":"10.1016\/j.iac.2023.05.001_bib33","unstructured":"www.cogentbio.com\/wp-content\/uploads\/2022\/12\/ASH-2022-Summit-TiP.pdf Accessed May 15, 2023."},{"issue":"2","key":"10.1016\/j.iac.2023.05.001_bib34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.iac.2023.05.001_bib35","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.jaip.2021.02.040","article-title":"Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: Prompt resolution of anaphylaxis with the addition of avapritinib","volume":"9","author":"Kudlaty","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.iac.2023.05.001_bib36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jaip.2015.03.015","article-title":"Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?","volume":"3","author":"Castells","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856123000462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856123000462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:53:09Z","timestamp":1760179989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856123000462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0889856123000462"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2023.05.001","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2023.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}